Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | PYGL | P06737 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26505052 | 1.00 | RAB9A (0.52) | RAB9ANPC1GRIK1PYGLMEN1 | |
| SCHEMBL26107843 | 0.81 | NPC1 (0.48) | RAB9ANPC1GRIK1PYGLMEN1 | |
| SCHEMBL26106853 | 0.75 | RAB9A (0.61) | RAB9ANPC1GRIK1PYGLMEN1 | |
| SCHEMBL30774378 | 0.74 | RAB9A (0.60) | RAB9ANPC1GRIK1PYGLMEN1 | |
| SCHEMBL29161484 | 0.74 | RAB9A (0.60) | RAB9ANPC1GRIK1PYGLMEN1 | |
| SCHEMBL8660904 | 0.71 | KMT2A (0.64) | RAB9ANPC1GRIK1MEN1KMT2A | |
| SCHEMBL26106684 | 0.71 | RAB9A (0.71) | RAB9ANPC1PYGLMEN1KMT2A | |
| SCHEMBL29022180 | 0.70 | RAB9A (0.53) | RAB9ANPC1GRIK1PYGLMEN1 | |
| SCHEMBL21828990 | 0.69 | RAB9A (0.72) | RAB9ANPC1GRIK1MEN1KMT2A | |
| SCHEMBL28769698 | 0.69 | KCNMA1 (0.54) | RAB9ANPC1GRIK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243188-A1 | METHIONINE ADENOSYLTRANSERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2025-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243188-A1 | METHIONINE ADENOSYLTRANSERASE 2A INHIBITORS | MAT2A, MAT2B, MAT1A | RAB9A 1337/4885NPC1 3170/4885GRIK1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.